AstraZeneca Opposes Petitions for Seroquel MDL

WASHINGTON, D.C. - AstraZenca Pharmaceuticals has opposed two petitions for the creation of a Seroquel MDL, saying the plaintiffs think the recent $700 million Zyprexa settlement creates an incentive for Seroquel MDL proceedings, which will give them "substantial settlement clout." In re Seroquel Litigation. MDL No. 1769 (JPML).

AstraZeneca filed its opposition on March 13, arguing that "[o]n the heels of the $700 million Zyprexa® settlement, two groups of plaintiffs have set their sights on the prescription medication Seroquel®, which, like Zyprexa®, is an atypical antipsychotic indicated for the treatment of schizophrenia."

The petitions will be considered at the JPML's …